Molbrick

Company Overview

Snapshot

Founded in January 2019 by Barak Akabayov, Molbrick operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing novel antimicrobial agents.

Business overview

Molbrick is a Health Tech & Life Sciences startup specializing in the development of novel antimicrobial agents designed to treat drug-resistant mycobacteria. The company's core technology involves small-molecule target cellular compartments essential for DNA replication, a platform developed in Dr. Barak Akabayov's lab at Ben-Gurion University. Molbrick operates within the Pharmaceuticals sector, targeting the healthcare and life sciences industries with its B2B business model.

Company Intelligence Q&A

What is Molbrick's primary focus?

Molbrick is focused on developing novel antimicrobial agents specifically designed to treat drug-resistant mycobacteria.

When was Molbrick founded?

Molbrick was founded in January 2019.

Who is the founder of Molbrick?

Barak Akabayov is the founder of Molbrick.

What is the stage of Molbrick's product development?

Molbrick's product is currently in the R&D stage, developing novel antimicrobial agents to treat drug-resistant mycobacteria.

What is the origin of Molbrick's platform technology?

Molbrick's platform technology was developed in Dr. Barak Akabayov's lab at Ben-Gurion University.